Nurix Therapeutics Inc
NASDAQ:NRIX
Intrinsic Value
Nurix Therapeutics, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one NRIX stock under the Base Case scenario is 29.65 USD. Compared to the current market price of 12.02 USD, Nurix Therapeutics Inc is Undervalued by 59%.
Valuation Backtest
Nurix Therapeutics Inc
Run backtest to discover the historical profit from buying and selling NRIX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Nurix Therapeutics Inc
Current Assets | 251m |
Cash & Short-Term Investments | 244m |
Other Current Assets | 7m |
Non-Current Assets | 61.7m |
Long-Term Investments | 10.3m |
PP&E | 47.2m |
Other Non-Current Assets | 4.2m |
Current Liabilities | 87.6m |
Accounts Payable | 5.9m |
Accrued Liabilities | 35.6m |
Other Current Liabilities | 46.1m |
Non-Current Liabilities | 56.3m |
Other Non-Current Liabilities | 56.3m |
Earnings Waterfall
Nurix Therapeutics Inc
Revenue
|
80.9m
USD
|
Operating Expenses
|
-238.2m
USD
|
Operating Income
|
-157.3m
USD
|
Other Expenses
|
12.6m
USD
|
Net Income
|
-144.7m
USD
|
Free Cash Flow Analysis
Nurix Therapeutics Inc
NRIX Profitability Score
Profitability Due Diligence
Nurix Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Nurix Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
NRIX Solvency Score
Solvency Due Diligence
Nurix Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Nurix Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NRIX Price Targets Summary
Nurix Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for NRIX is 25.09 USD with a low forecast of 14.14 USD and a high forecast of 36.75 USD.
Ownership
NRIX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NRIX Price
Nurix Therapeutics Inc
Average Annual Return | -0.35% |
Standard Deviation of Annual Returns | 67.78% |
Max Drawdown | -92% |
Market Capitalization | 659.9m USD |
Shares Outstanding | 54 903 400 |
Percentage of Shares Shorted | 15.87% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nurix Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 242 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other challenging diseases. The company leverages its DELigase, an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607, DeTIL-0255, KINASE-CTM3, COVID-CTMs, LIGASE-INH2 and DeCART. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Its KINASE-CTM3, a kinase involved in T cell growth and activation to treat T cell malignancies and autoimmune disease.
Contact
IPO
Employees
Officers
The intrinsic value of one NRIX stock under the Base Case scenario is 29.65 USD.
Compared to the current market price of 12.02 USD, Nurix Therapeutics Inc is Undervalued by 59%.